|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
H.B. 1287
|
|
VETOES
|
|
|
|
|
|
|
|
|
including but not limited to physicians, nurses, pharmacists, hospitals, and advocates
to examine prescription drug monitoring and other ways to limit prescription drug
abuse and diversion. This is an important issue that must be addressed in the
appropriate manner. The advisory group will focus on issues such as the use of
electronic records, electronic monitoring of controlled drug prescriptions, a standard
of care for pain management, patient confidentiality, and will emphasize the
treatment of addiction. DHMH and the Maryland Health Care Commission will be
required to report on their progress and recommendations prior to the end of this year
so that Maryland can move forward to address these important issues.
For the above stated reason, I have vetoed House Bill 1287.
Very truly yours,
Robert L. Ehrlich, Jr.
Governor
House Bill No. 1287
AN ACT concerning
Prescription Drug Monitoring Program
FOR the purpose of establishing requiring the Department of Health and Mental
Hygiene to establish and maintain a certain Prescription Drug Monitoring
Program within the Department of Health and Mental Hygiene; establishing
the powers and duties of the Secretary of Health and Mental Hygiene under the
Program; requiring prescription monitoring data to be destroyed after a certain
time period unless a certain request for retention of certain information is
submitted to the Department; creating a certain Advisory Board on Prescription
Drug Monitoring to assist in the design, implementation, and evaluation of the
Program; establishing the chair, the terms of the members, and the
responsibilities of the Board; creating requiring the Secretary to appoint a
multidisciplinary consultation team to assist in the interpretation of
prescription monitoring data; requiring dispensers to submit electronically
certain information to the Program except in certain circumstances; prohibiting
the Board and the Secretary from charging a fee or imposing an assessment on
certain persons for certain purposes; making prescription monitoring data
confidential and privileged and not subject to certain means of legal compulsion
except under certain circumstances; authorizing certain agencies and persons to
obtain access to prescription monitoring data under certain circumstances;
establishing immunity from civil liability for certain agencies and persons
relating to the operation and use of the Program; providing for education and
training relating to the Program; establishing penalties for violations of the
requirements of the Program; defining certain terms; providing that
implementation of the Program is contingent on the Board obtaining certain
federal, State, or private funds; prohibiting the Program from collecting
prescription monitoring data before a certain date; and generally relating to the
creation and operation of the Prescription Drug Monitoring Program.
BY adding to
- 3820 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
